Insilico Biotechnology AG

Insilico Biotechnology AG delivers predictive Digital Twins for the biopharmaceutical industry. Insilico Digital Twins lead to superior productivity, product quality and process robustness by using artificial intelligence and mechanistic knowledge. As a result, Insilico's unique approach substantially reduces costs of manufacturing and time to market. Leading biopharmaceutical companies worldwide use Insilico Digital Twins for process development and manufacturing of drugs. Founded in 2001, Insilico Biotechnology is a privately held company based in Stuttgart, Germany.

Since 2001, our interdisciplinary approach helped us to consolidate competitive advantages by providing new insights in our operating fields and generating novel IP for our customers. Scalable software modules within the Insilico Platform Solution automatically deliver actionable results from process data. Our experts are passionate about sharing their many years of experience to drive effective technology transfer. 

Insilico aims to deliver outstanding results to customers and shareholders by acting in an agile and transparent way. We value differing opinions, cultures and backgrounds, as diverse teams are a key success factor. Continuous improvement is paramount to becoming the leading supplier of innovative predictive Digital Twins for bio-pharmaceutical companies. We provide enterprise software solutions for predictive biomanufacturing using Digital Twins. The biopharma industry uses our software to accelerate time-to-market, to mitigate risks, and to capitalize on the value of data.